Status BioPharma Publicizes Grand Opening of World-Scale Vaccine Heart in South Korea

SINGAPORE, December 01, 2021–(BUSINESS WIRE)–Status BioPharma Restricted (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, is happy to announce the grand opening of its global-scale Vaccine Heart in Osong, South Korea.

This press launch options multimedia. View the complete launch right here:

Status Biopharma Vaccine Heart (Photograph: Enterprise Wire)

The opening ceremony was held on December 01, 2021 on the Vaccine Heart in Osong Campus. The ceremony was attended by many distinguished company together with Minister for Authorities Coverage Coordination Mr. Yun-cheol Koo, Deputy Governor Mr. Il-hong Seong of Chungbuk Province, Mayor of Cheongju Metropolis Mr. Beom-deok Han, Representatives from Octava Fund Restricted Mr. Joseph Tey and Mr. Sze Khai Pang.

PBP commenced building of its Vaccine Heart April this yr and accomplished the global-scale manufacturing facility with a complete space of 10,342.88 m2 and a complete capability of 104,000 litres (52 models of two,000 liter bioreactors) in solely eight months by using Status Biologics (334970: KOSDAQ)’ proprietary engineering expertise, ALITA Sensible BioFactoryTM. With the ALITA system which supplies mixed benefits of Stainless Metal & Single-Use system, various kinds of vaccines might be produced in versatile customized manufacturing suites. The Vaccine Heart’s Single-Use bioreactors additionally improve operational effectivity and productiveness whereas minimizing the chance of cross contamination.

PBP is at the moment specializing in two COVID19 vaccine tasks to provide Sputink V and Sputink Mild vaccines. PBP’s global-scale Vaccine Heart is able to producing round 2.6 billion doses of the primary dose of Sputnik V vaccine (Ad26 adenovirus vector) per yr.

The middle will quickly be ready to provide different sorts of vaccines together with mRNA vaccines to actively reply to the rising calls for of COVID19 vaccines.

The corporate in the end goals to develop its personal vaccine merchandise to fight potential future pandemics and PBP Vaccine Heart would be the basecamp for this journey.

PBP’s CEO, Dr Lisa S. Park commented, “We’re more than happy to finish the Status Biopharma Vaccine Heart as deliberate this yr with our Group’s distinctive and unmatched engineering expertise, ALITA Sensible BioFactory” and “this Vaccine Heart can be enjoying a big position in our struggle in opposition to Covid-19 and doable future pandemics”.

View supply model on


Media enquiries:
World Communication Workforce
Status BioPharma Ltd.
Yujin Suh
Tel: +65-6924-6535
[email protected]
[email protected]

Previous post FTI Consulting (FCN) Up on International Enterprise, Money Energy
Next post Alibaba empowers enterprise items to be extra agile as challenges mount